Sign In
Buy TXG
$31.75
-0.470 (-1.46%)
At Close: Jun 16, 2026
10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates
06:50pm, Wednesday, 02'nd Nov 2022
10x Genomics (TXG) delivered earnings and revenue surprises of 17.78% and 1.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Boring Stocks with Exciting Profit Potential
09:17am, Thursday, 27'th Oct 2022
There's nothing wrong with holding a portfolio consisting of boring stocks. You know, the kind of steady blue-chip stocks that don't necessarily perform as well in a bull market but hold steady in a b
10x Genomics to Report Third Quarter Financial Results on November 2, 2022
04:05pm, Wednesday, 12'th Oct 2022
PLEASANTON, Calif. , Oct. 12, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2022 after market close on Wednesday, November 2,
Got $2,000? Consider Buying These 2 Beaten-Down Cathie Wood Stocks at Your Own Risk
10:00am, Friday, 07'th Oct 2022
Their long-term plans are ambitious, but they haven't performed well as investments recently.
Should You Buy the Nasdaq's 10 Worst-Performing 2022 Stocks?
06:16am, Thursday, 08'th Sep 2022
The best performer on this list has lost three-fourths of its value this year.
10x Genomics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
04:05pm, Friday, 02'nd Sep 2022
PLEASANTON, Calif. , Sept. 2, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be pa
10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q2 2022 Results - Earnings Call Transcript
08:49pm, Monday, 08'th Aug 2022
10x Genomics, Inc. (NASDAQ:TXG ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Cassie Corneau - Investor Relations and Strategic Finance Serge Saxonov - Chief Executi
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
08:20pm, Monday, 08'th Aug 2022
10x Genomics (TXG) delivered earnings and revenue surprises of -42.50% and 0.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Torex Gold Resources' (TORXF) CEO Jody Kuzenko on Q2 2022 Results - Earnings Call Transcript
11:10am, Saturday, 06'th Aug 2022
Torex Gold Resources, Inc. (OTCPK:TORXF) Q2 2022 Earnings Conference Call August 4, 2022 9:00 AM ET Company Participants Dan Rollins - SVP, Corporate Development & IR Jody Kuzenko - President & CEO An
Analysts Estimate 10x Genomics (TXG) to Report a Decline in Earnings: What to Look Out for
11:37am, Monday, 01'st Aug 2022
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments
12:23pm, Wednesday, 27'th Jul 2022
Cytek and 10x Genomics both offer single cell visualization tools, a growing and important field in modern medicine. However, each company sees huge differences in popularity, financial performance, a
10x Genomics stock suffering record drop toward record low after revenue warnings prompts downgrade
11:09am, Friday, 15'th Jul 2022
Shares of 10x Genomics Inc. TGX, -4.32% plunged 22.3% in active morning trading Friday, putting them on track to suffer a record one-day drop to a record low Friday, after the biotechnology company's
10X Genomics Reports Q2 Preliminary Revenues, Shares Plummet On Missing Street Expectation
05:03pm, Thursday, 14'th Jul 2022
10X Genomics Inc (NASDAQ: TXG) reported preliminary second-quarter revenue is expected to be ~$114.5 million, a decrease of 1% year-over-year, below the consensus of $127.7 million. The company see
10x Genomics stock falls as revenue forecast disappoints
04:31pm, Thursday, 14'th Jul 2022
Shares of 10x Genomics Inc. TXG, -7.74% fell in the extended session Thursday after the biotech company said it expects second-quarter revenue to come in below Wall Street expectations. 10x Genomics s
3 Gene Sequencing Stocks With Potential to Gain in 2H22
10:45am, Wednesday, 13'th Jul 2022
Here we look at three stocks, PKI, TMO and TXG, with robust genome sequencing capabilities that investors can keep a watch on.
